P. Morlat, Prise en charge médicale des personnes vivant avec le VIH Rapport 2013: recommandations du groupe d'experts, DILA -Direction de l'information légale et administrative : La documentation française, Ministère des affaires sociales et de la santé, 2012. ,
URL : https://hal.archives-ouvertes.fr/in2p3-00019242
,
No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.61, pp.1715-1725, 2015. ,
In-utero ART exposure and the need for pharmacovigilance, Lancet Glob. Health, vol.6, issue.18, pp.30272-30281, 2018. ,
,
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial, HIV Clin. Trials, vol.19, pp.129-138, 2018. ,
,
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, openlabel, phase 2b, non-inferiority trial, Lancet Lond. Engl, vol.390, pp.31917-31924, 2017. ,
,
LAI116482 Study Team, Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial, Lancet Infect. Dis, vol.15, pp.152-160, 2015. ,
,
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. inferiority trial, Lancet Lond. Engl, vol.390, issue.17, pp.32340-32341, 2017. ,
, Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps, vol.58, pp.309-323, 2019.
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana, N. Engl. J. Med, vol.381, pp.827-840, 2019. ,
,
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir, J. Acquir. Immune Defic. Syndr, vol.81, pp.371-378, 1999. ,
,
, Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection -15 Jurisdictions, vol.69, pp.1-5, 2013.
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs, Eur. J. Obstet. Gynecol. Reprod. Biol, vol.147, pp.157-160, 2009. ,
Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model, Am. J. Obstet. Gynecol, vol.198, pp.433-434, 2008. ,
Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am. J. Obstet. Gynecol, vol.213, pp.1-6, 2015. ,
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways, Clin. Pharmacokinet, vol.56, pp.537-550, 2017. ,
Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy, Am. J. Obstet. Gynecol, vol.210, p.1, 2014. ,
,
Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor, HIV Clin. Trials, vol.14, pp.192-203, 2013. ,
Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, AIDS Lond. Engl, vol.32, pp.321-325, 2018. ,
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model, Am. J. Obstet. Gynecol, vol.195, pp.296-301, 2006. ,
Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model, Obstet. Gynecol. Int, 2009. ,
Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob. Agents Chemother, vol.58, pp.5617-5620, 2014. ,
Flow-dependent transfer of antipyrine in the human placenta in vitro, Reprod. Nutr. Dev, vol.23, pp.41-50, 1983. ,
URL : https://hal.archives-ouvertes.fr/hal-00898027
Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am. J. Obstet. Gynecol, vol.114, pp.822-828, 1972. ,
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression, Antimicrob. Agents Chemother, vol.57, pp.1415-1420, 2013. ,
Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model, Antimicrob. Agents Chemother, vol.59, pp.2901-2903, 2015. ,
Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited, 2020. ,
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed. Chromatogr. BMC, vol.21, pp.1095-1104, 2007. ,
HIV: dolutegravir should be preferred treatment option in all populations, says WHO, BMJ, vol.366, 2019. ,
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy, Antimicrob. Agents Chemother, vol.59, pp.3660-3662, 2015. ,
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study), PLoS Med, vol.16, 2019. ,
Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model, PloS One, vol.14, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02272841
Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model, J. Antimicrob. Chemother, vol.71, pp.480-483, 2016. ,
,
,
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob. Agents Chemother, vol.60, pp.3112-3114, 2016. ,
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans, Xenobiotica Fate Foreign Compd. Biol. Syst, vol.46, pp.147-162, 2016. ,
National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units, Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy, Am. J. Obstet. Gynecol, vol.192, pp.633-639, 2005. ,
Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited, 2020. ,
Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer, J. Clin. Pharmacol, vol.59, issue.1, pp.70-81, 2019. ,
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors, Clin. Pharmacokinet, vol.56, pp.25-40, 2017. ,
Long-acting injectable cabotegravir for the prevention of HIV infection, Curr. Opin. HIV AIDS, vol.15, pp.19-26, 2020. ,
Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models, Br. J. Clin. Pharmacol, vol.81, pp.646-657, 2016. ,
Criteria and challenges of the human placental perfusion -Data from a large series of perfusions, Toxicol. Vitro Int. J. Publ. Assoc. BIBRA, vol.29, pp.1482-1491, 2015. ,
The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs, Clin. Pharmacol. Ther, vol.90, pp.67-76, 2011. ,